Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

NCT06711523 PHASE3 ACTIVE_NOT_RECRUITING

To evaluate the efficacy, safety, and immunogenicity of PEG-G-CSF Injection (Kexing Biopharmaceutical Co., Ltd.) for the prevention of neutropenia after chemotherapy, using the PEG-G-CSF Injection ( Neulasta®, Amgen Europe B.V.) as a positive control.

Details

Lead sponsor	Kexing Biopharm Co., Ltd.
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	250
Start date	Thu Jan 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jun 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Neutropenia, Chemotherapy-Induced Febrile
• Breast Neoplasm Female

Interventions

• PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)
• PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)

Countries

China